Madrigal Pharmaceuticals, INC. (MDGL) SEC Filings — 2025
13 SEC filings for Madrigal Pharmaceuticals, INC. (MDGL) in 2025.
Filings
- Madrigal Pharmaceuticals Announces Director, Officer, and Compensation Changes — 8-K · Dec 11, 2025
- Madrigal's Rezdiffra Fuels Revenue Surge Amidst Rising Costs — 10-Q · Nov 4, 2025
- Madrigal's Q2 Loss Widens to $150M Amid R&D Push — 10-Q · Aug 5, 2025
- Madrigal Pharmaceuticals Files 8-K — 8-K · Jul 30, 2025
- Madrigal Pharmaceuticals Terminates Agreement, Enters New One — 8-K · Jul 22, 2025
- Madrigal Pharmaceuticals Files 8-K for Security Holder Vote — 8-K · Jun 20, 2025
- Madrigal Pharmaceuticals Files Q1 2025 10-Q Report — 10-Q · May 1, 2025
- Madrigal Pharma Files Definitive Proxy Statement — DEF 14A · Apr 29, 2025
- Madrigal Pharma Appoints New Chief Medical Officer — 8-K · Apr 17, 2025
- Madrigal Pharma Appoints New Chief Medical Officer — 8-K · Mar 11, 2025
- Madrigal Pharmaceuticals Files 8-K on Financials — 8-K · Feb 26, 2025
- Madrigal Pharmaceuticals Files 2024 10-K — 10-K · Feb 26, 2025
- Madrigal Pharmaceuticals Files 8-K — 8-K · Jan 13, 2025